{"filings":[{"id":2383836,"accession_number":"0001193125-26-359300","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-08-20T20:46:06+00:00","items":["8.01"],"status":"ready","headline":"Personalis wins $18.3M VA task order; cumulative VA MVP value $243.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New task order under VA Million Veteran Program contract, effective Sept 30, 2026, valued up to $18.3M.","Cumulative value of VA MVP task orders now approximately $243.3M.","Revenue contingent on sample receipt from VA MVP and service performance.","No change to prior guidance; order adds to existing contract backlog."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2051396,"accession_number":"0001193125-26-332748","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-08-04T20:04:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q2 revenue up 30% to $22.4M; clinical test volume surges 199% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Clinical test volume of 10,384, up 199% YoY and 33% sequentially; clinical revenue $2.6M (+442% YoY).","Total revenue $22.4M (+30% YoY); pharma testing & other revenue $16.8M (+51%); VA MVP revenue $3.0M (-9%).","Cash and investments $212.7M; secured Medicare coverage for NeXT Personal IO monitoring and neoadjuvant breast cancer.","VICTORI study: NeXT Personal detected 100% of relapses; TRACERx data highlights sub-10 ppm sensitivity in lung cancer.","Due to pending merger with Tempus AI, company will no longer provide financial guidance or hold earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1750757,"accession_number":"0001193125-26-309101","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-07-20T21:26:43+00:00","items":["1.01","9.01"],"status":"ready","headline":"Personalis to be acquired by Tempus AI; $16.25 per share cash or stock election","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each Personalis share converts to $16.25 cash (if Tempus elects cash for up to 50% of shares) or Tempus shares based on exchange ratio (floor 0.3356, or $16.25/Tempus VWAP if above $48.42).","Merck, holding ~13% of Personalis, enters voting agreement to support the merger.","Termination fee of ~$76.8 million payable by either party under specified conditions.","Closing conditions include stockholder approval, HSR clearance, and tax opinion.","Transaction expected to close by April 20, 2027, with possible extensions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1731796,"accession_number":"0001193125-26-308488","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-07-20T13:18:31+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus to acquire Personalis for $16.25/share, $1.5B enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration of $16.25 per share, 6% premium to last close, 28% premium to 30-day VWAP.","Total enterprise value of $1.5B net of Tempus' existing ownership; 100% stock with cash option up to 50%.","Closing expected late 2026 or early 2027; subject to Personalis shareholder and regulatory approvals.","Personalis reports preliminary Q2 revenue of $22.4M and 10,384 clinical tests, up 33% QoQ.","Acquisition combines Personalis' MRD technology with Tempus' AI platform; MRD market opportunity $20B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554239,"accession_number":"0001193125-26-232533","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-20T20:04:03+00:00","items":["8.01"],"status":"ready","headline":"CMS expands Medicare coverage for Personalis's NeXT Personal test to monitor neoadjuvant therapy in breast cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.","Expansion effective May 19, 2026, under CMS Molecular Diagnostics Program.","NeXT Personal is an ultrasensitive liquid biopsy test; this indication broadens addressable patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69961,"accession_number":"0001193125-26-221846","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-13T20:52:20+00:00","items":["5.07"],"status":"ready","headline":"Personalis stockholders elect directors, ratify auditor, approve exec compensation at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Olivia K. Bloom and Woodrow A. Myers, Jr., M.D. elected as Class I directors for three-year terms.","Ratification of BDO USA, P.C. as independent auditor for FY 2026: 91,586,300 for, 34,421 against.","Non-binding advisory vote on named executive officer compensation passed: 75,549,455 for, 384,918 against.","Quorum of 91,869,300 shares (87.76%) present at May 12, 2026 virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67884,"accession_number":"0001193125-26-221574","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-13T20:03:04+00:00","items":["8.01"],"status":"ready","headline":"CMS expands Medicare coverage for Personalis' NeXT Personal test to immunotherapy monitoring","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS coverage now includes immunotherapy monitoring for late-stage solid tumor patients as of May 12, 2026.","NeXT Personal is an ultrasensitive liquid biopsy test; the expanded indication broadens the addressable patient population.","No financial impact or revenue guidance was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93445,"accession_number":"0001193125-26-211850","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q1 clinical test volume +258% YoY to 7,815; secures Medicare coverage for lung cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.5M vs $20.6M YoY; clinical revenue $1.4M vs $0.3M as non-core revenue declined.","Cash, equivalents & short-term investments $233.2M; includes ~$21M net from ATM at $10.00/share.","Full-year 2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45k, net loss ~$105M.","Second Medicare coverage in six months (lung cancer surveillance) follows prior breast cancer win.","CEO states 'Win-in-MRD' strategy working; clinical revenue expected to grow five-fold in 2026."],"consensus_eps_estimate":-0.2751,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":15472000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105064,"accession_number":"0001193125-26-110852","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Personalis appoints Richard Chen as President; CEO Hall steps down from President role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Chen appointed President effective March 13, 2026; he retains EVP R&D and CMO roles.","Annual base salary raised to $570,000 effective April 1, 2026; performance bonus target increased to 70% of base.","Granted option to purchase 37,500 shares (closing price on March 13, 2026) vesting over 36 months.","Granted RSU award of 6,250 shares vesting one-sixth at six-month anniversary, then bi-annually thereafter.","Christopher Hall, CEO, previously held President role; no other changes to Board or executive team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105063,"accession_number":"0001193125-26-076553","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.","Total FY2025 revenue $69.6M (down 18% YoY); clinical test revenue more than doubled to $2.0M.","Ended 2025 with ~$240M cash, including $109M net from ATM at $8.43/share average.","Secured Medicare coverage for breast and lung cancer surveillance; key catalyst for MRD.","FY2026 guidance: total revenue $78-80M, clinical revenue $10-11M (5x growth), net loss ~$105M."],"consensus_eps_estimate":-0.299,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":69648000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105062,"accession_number":"0001193125-26-007037","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).","Clinical test volume of 16,233 in FY2025, up ~400% YoY; Q4 alone 6,183 tests (+41% vs Q3).","Clinical test revenue doubled to ~$2.0M in FY2025 (2024: $0.8M).","Cash, equivalents, and short-term investments ~$240M, including $109M from ATM at $8.43/share.","Secured Medicare coverage for breast cancer surveillance, a key reimbursement milestone."],"consensus_eps_estimate":-0.299,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":69648000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121316,"accession_number":"0001193125-25-302644","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Personalis files prospectus supplement for up to $100M at-the-market stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100 million of common stock may be sold under amended ATM sales agreement with Piper Sandler and BTIG.","Offering is in addition to the existing ATM facility from December 2024.","Cooley LLP legal opinion on the shares is filed as Exhibit 5.1.","Proceeds intended for general corporate purposes, no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121315,"accession_number":"0001193125-25-294454","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis gets CMS revised reimbursement rates for NeXT Personal breast cancer test","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS revised reimbursement for Personalis' NeXT Personal Dx Breast MRD test to $4,266 effective Dec 1, 2025","Reimbursement for NeXT Personal Single Plasma Test set at $1,164, available up to six years post-treatment","Medicare coverage for the NeXT Personal Dx test is available once per cancer diagnosis for stage II/III breast cancer"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121314,"accession_number":"0001193125-25-273416","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.","Reimbursement rate $3,878 for NeXT Personal Dx Breast MRD test; $1,158 for NeXT Personal Single Plasma Test.","Coverage effective retroactively from October 7, 2025; Single Plasma test available up to 6 years post-treatment.","Dx Breast MRD test covered once per cancer diagnosis; expands market access for Personalis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121313,"accession_number":"0001193125-25-264690","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q3 revenue down 44% to $14.5M; clinical tests up 364% YoY; FY guidance reduced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.5M (-44% YoY); net loss $21.7M ($0.24/sh) vs $39.1M ($0.64) in Q3 2024, prior year included $26M warrant expense.","Delivered 4,388 clinical tests, +26% sequential and +364% YoY; submitted third Medicare dossier for lung cancer.","FY 2025 revenue guidance narrowed to $68-73M (from $70-80M); clinical tests reimbursed cut to $1.5-2M from $3-6M.","Cash, cash equivalents and investments $150.5M; cash used in operations and capex $23.4M in Q3.","Q4 2025 revenue outlook $15.7-20.7M; pharma/services revenue $12-17M; population sequencing ~$3.7M."],"consensus_eps_estimate":-0.2842,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":52303000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137972,"accession_number":"0000950170-25-110739","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis receives $13.5M new task order under VA Million Veteran Program contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New task order effective Sept 30, 2025, valued up to $13.5M subject to sample receipt and service performance.","Cumulative value of all task orders under VA MVP contracts now approximately $225.0M.","Contract with U.S. Department of Veterans Affairs for Million Veteran Program continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137971,"accession_number":"0001193125-25-173575","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Reports Q2 2025 Revenue of $17.2M, Net Loss $20.1M; Clinical Test Volume Up 59% Sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025.","Revenue decreased 24% to $17.2M from $22.6M in Q2 2024, partly due to $5.6M decline from Natera.","Net loss was $20.1M ($0.23 per share) versus $12.8M ($0.24 per share) in Q2 2024.","Expanded Tempus AI collaboration to include colorectal cancer for exclusive commercialization.","Lowered full-year 2025 revenue guidance to $70-80M from $80-90M, citing biopharma headwinds."],"consensus_eps_estimate":-0.2486,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":37808000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137970,"accession_number":"0001193125-25-157096","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.","Agreement term extended to November 25, 2029.","Exclusivity period extended to December 31, 2028 for both parties on tumor-informed MRD in these indications.","Standstill restrictions for Tempus modified to expire June 4, 2027 or end of exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155357,"accession_number":"0000950170-25-074346","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Personalis annual meeting: directors elected, auditor ratified, say-on-pay passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["A. Blaine Bowman elected as Class III director with 58.2M for, 710K withheld; Karin Eastham with 53.7M for, 5.2M withheld.","Ratification of BDO USA as auditor for FY2025: 76.6M for, 110K against, 112K abstentions.","Advisory vote on named executive officer compensation approved: 56.6M for, 2.2M against, 38K abstentions.","Quorum of 87.0% of outstanding shares (76.8M of 88.3M) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155356,"accession_number":"0001193125-25-113820","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).","Net loss $15.8M ($0.18/share) vs $13.0M ($0.26) in Q1 2024; per-share improved on higher share count.","Clinical test volume 2,184, up 52% from Q4 2024; NeXT Personal data in CRC and breast cancer submitted for Medicare.","Raised $17.8M net from ATM at $5.89/share; cash $185.7M; operations cash use $20.5M.","FY2025 revenue guidance unchanged $80-90M; gross margin raised to 22%-24%; net loss guidance narrowed to ~$83M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":20605000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173872,"accession_number":"0001193125-25-039219","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports FY24 revenue $84.6M (+15% YoY); provides FY25 guidance with $80-90M revenue, net loss ~$85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.","Q4 revenue $16.8M (-15% YoY); delivered 1,441 molecular tests in Q4 (+52% QoQ); FY24 tests 3,285 vs 177 in FY23.","Guidance: FY25 revenue $80-90M, gross margin 21-23%, net loss ~$85M, cash usage $75-80M (up from $47M in FY24).","Business highlights: submitted for Medicare coverage in early-stage breast cancer; multi-year Moderna extension; expanded Tempus deal."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":84614000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173871,"accession_number":"0001193125-25-002872","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports FY2024 revenue ~$84.6M (+15% YoY), above guidance; cash ~$185M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue of ~$84.6M, up 15% from $73.5M in 2023, above guidance range of $83-84M.","Pharma/enterprise/other revenue grew 20% to ~$77.2M despite Natera revenue declining 20% to ~$25.4M.","Q4 revenue of ~$16.8M (down 15% YoY); delivered 1,441 molecular tests, up 52% from Q3.","Cash, cash equivalents, and short-term investments of ~$185.0M, including $50M strategic investment from Merck; path to cash flow break-even."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":84614000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190842,"accession_number":"0001193125-24-285922","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Personalis enters amended ATM equity sales agreement with Piper Sandler and BTIG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended and Restated ATM Sales Agreement dated Dec 27, 2024 with Piper Sandler & Co. and BTIG, LLC as sales agents.","Company may offer and sell shares of common stock from time to time through the agents under the ATM program.","Prospectus supplement filed to shelf registration statement (Form S-3) relating to the offering of shares.","Previous sales agreement prospectus from January 2024 terminated; no further offers under that program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190841,"accession_number":"0001193125-24-281696","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Personalis secures $50M Merck investment, extends Moderna pact, expands Tempus deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merck to purchase 14,044,943 shares at $3.56/share for ~$50M; closing expected Dec 19, 2024.","Merck receives standstill, information, pro-rata participation, and voting rights until 2 years post-close.","Tempus AI authorized to sell NeXT Personal minimal residual disease test to pharma/biotech clients.","Moderna extends SOW for V940/mRNA-4157 INT program to up to 10 years; Moderna can license IP for low double-digit millions.","Personalis to use $10M of proceeds to open ISO-certified lab outside US, mutually agreed with Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190840,"accession_number":"0000950170-24-122230","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q3 revenue $25.7M (+41% YoY); raises FY 2024 guidance to $83-84M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25.7M, up 41% YoY; biopharma revenue $15.7M (+96% YoY).","Net loss $39.1M includes $26.0M non-cash warrant expense; cash $143.7M.","Raised FY2024 revenue guidance to $83-84M from $79-81M; Q4 revenue expected $15-16M.","Delivered 945 molecular tests in Q3, a 68% sequential increase.","Raised ~$62.2M net from Tempus warrant exercise and ATM stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":67814000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207322,"accession_number":"0000950170-24-108191","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis receives $7.5M new task order from VA Million Veteran Program; cumulative orders reach $210.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New task order under VA Million Veteran Program contract effective Sept. 30, 2024, valued up to $7.5M.","Cumulative task order value under VA MVP contracts now approximately $210.7 million.","Revenue recognition subject to receipt of samples from VA and performance of services by Personalis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207321,"accession_number":"0001193125-24-201697","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Tempus invests $36M in Personalis, exercises warrants and buys shares; expands commercial collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tempus exercises warrants for 9.2M shares at avg $2.00 ($18.4M) and buys 3.5M shares at $5.07 ($17.7M).","Total investment ~$36M; Tempus will own ~19.3% of Personalis outstanding common stock.","Partners accelerate commercialization of ultra-sensitive MRD testing for breast, lung, and immunotherapy monitoring.","Personalis to increase patient sample capacity; Tempus expands commercialization efforts over first two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207320,"accession_number":"0000950170-24-092712","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).","Net loss $12.8M, improved from $24.0M loss in Q2 2023; cash $87.0M.","FY 2024 revenue guidance raised to $79-81M from $76-78M; non-GAAP net loss ~$75M.","Cross-license agreement with Myriad Genetics; settled IP lawsuit with Foresight Diagnostics.","Delivered 561 molecular tests in Q2, up 66% QoQ; launched NeXT Personal Dx with Tempus AI."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":42105000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224725,"accession_number":"0000950170-24-078618","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Personalis settles patent litigation with Foresight, grants license for MRD tests, receives tiered royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settled pending infringement claims and IPR proceedings with Foresight Diagnostics.","Foresight gets non-exclusive license under Personalis patents for WGS-based MRD tests using phased variants.","Foresight to pay low-single digit tiered royalty on net sales of licensed products/services.","Upon a change of control involving specified acquirers, a low single-digit million one-time fee and slight royalty rate increase apply.","License is perpetual except for patent challenge termination; each party releases claims and covenants not to sue on CNS patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224724,"accession_number":"0000950170-24-062886","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Personalis annual meeting: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Christopher Hall, Lonnie Shoff, Kenneth J. Widder elected Class II directors until 2027.","BDO USA ratified as independent auditor for FY2024 with 40,946,872 votes for.","Advisory say-on-pay on named executive officers passed with 25,393,708 votes for.","Broker non-votes of 15,492,304 shares on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224723,"accession_number":"0000950170-24-055585","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.","Net loss narrowed to $13.0M from $28.7M in Q1 2023, aided by $4.8M non-cash gain on Tempus warrants.","Raised FY2024 total revenue guidance to $76-78M from $73-75M; non-GAAP net loss improved to ~$77M from prior ~$80M.","Cash and short-term investments $95.4M; Q2 2024 revenue expected $19.5-20.5M.","NeXT Personal MRD test published in Oncotarget; 338 molecular tests delivered; five ASCO abstracts accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":19525000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243993,"accession_number":"0000950170-24-022032","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q4 revenue $19.7M (+18% YoY); FY2024 revenue guidance $73-75M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $19.7M (+18% YoY); FY2023 revenue $73.5M (+13% YoY).","Q4 net loss $26.6M ($0.54 EPS); FY net loss $108.3M ($2.25 EPS).","FY2024 guidance: revenue $73-75M, net loss ~$80M (down from $108.3M), cash usage ~$62M.","Obtained final Medicare coverage for NeXT Dx tumor profiling test; partnerships with Tempus, Myriad, ClearNote, and Natera extension."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":73481000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243992,"accession_number":"0000950170-24-002304","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports Q4 revenue of $19.7M (+18% YoY); cash runway extended to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 revenue $19.7M, up 18% YoY from $16.7M; full-year revenue $73.5M, up 13%.","Natera revenue in Q4 was $7.1M (vs $8.2M prior year); pharma/enterprise/other revenue $18.7M.","Cash and short-term investments $114.0M; cash usage reduced to ~$54M in 2023 from $119M.","Annual cost-cutting reduced expenses by ~$35M; cash runway extended to Q1 2026.","CEO cites NeXT Personal Dx launch, Tempus partnership, and progress on clinical evidence."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":73481000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261396,"accession_number":"0000950170-23-067887","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis extends Natera minimum volume commitment deadline to end of 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Natera's minimum volume commitment extended from Q1 2024 to end of 2024, with option for further extension.","Natera obligation contingent on Personalis meeting specified quality metrics and turnaround times.","Agreement modification effective November 30, 2023; disclosed in 8-K filed December 4, 2023.","No financial terms of the extension were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261395,"accession_number":"0000950170-23-067383","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["2.05","7.01"],"status":"ready","headline":"Personalis cuts up to 65 jobs, estimates $4M charge and $14M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction in workforce of up to 65 employees; completion expected by end of January 2024.","Estimated severance and benefit charges of ~$4 million, primarily in Q4 2023; substantially all cash.","Expected ~$14 million savings in FY2024 operating expenses (salary, bonuses, taxes, benefits, stock-based comp)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261394,"accession_number":"0000950170-23-066458","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Personalis enters commercialization agreement with Tempus Labs for NeXT Personal Dx assay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tempus will pay Personalis up to $12,000,000 in Market Development Fee, including a $3M activation fee.","Personalis issued two warrants to Tempus to purchase up to 4,609,400 shares each at $1.50 and $2.50 per share.","Tempus will market Personalis' NeXT Personal Dx assay for breast cancer, lung cancer, and immuno-oncology monitoring.","The agreement has a five-year term with exclusivity until December 31, 2027, and includes milestones for up to $12M in fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261393,"accession_number":"0000950170-23-060202","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q3 revenue up 23% to $18.2M; raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.2M (+23% YoY); net loss $29.1M, EPS -$0.60 including $5.6M impairment.","Full-year 2023 revenue guidance raised to $73-74M (prior $70-72M); Q4 guided $19-20M.","Pharma/enterprise revenue $15.8M (+7% YoY); Natera contributed $7.9M.","TRACERx data: NeXT Personal up to 4x sensitivity vs other liquid biopsies; detects lung cancer 6-11 months before imaging.","Cash $120.7M; FY2023 cash usage <$70M vs $119M in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":53806000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278638,"accession_number":"0000950170-23-044814","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis receives $7.5M VA task order; MVP backlog rises to $203.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New task order from U.S. Department of Veterans Affairs under Million Veteran Program valued up to $7.5M.","Task order effective September 30, 2023, contingent on sample receipt and service performance.","Cumulative value of task orders under VA MVP contract increased to approximately $203.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278637,"accession_number":"0000950170-23-039759","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q2 revenue $16.7M (-8% YoY); net loss $24.0M; tightens FY guidance to $70-72M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $16.7M vs $18.2M in Q2 2022, an 8% decrease; pharma/enterprise revenue $13.7M, down 3%.","Net loss $24.0M ($0.50 EPS) vs $24.8M loss in Q2 2022; cash and investments $137.2M as of June 30.","FY 2023 revenue guidance tightened to $70M-$72M; net loss expected ~$103M, cash usage ~$70M.","VA MVP exercised first of four one-year renewal options; second patent lawsuit filed against Foresight Diagnostics.","Announced collaboration with National Cancer Center Hospital East and Ono Pharmaceutical for rectal cancer biomarker analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":35559000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296853,"accession_number":"0000950170-23-027795","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Alan Colowick resigns; Kenneth Widder appointed to Personalis board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Colowick resigned as director on June 12, 2023; no disagreement cited.","Board appointed Kenneth Widder as Class II director effective June 13, 2023.","Widder qualifies as independent under Nasdaq Rule 5605(a)(2); term expires at 2024 annual meeting.","Widder to receive standard non-employee director compensation: cash retainers, initial and annual equity grants.","Company entered standard indemnification agreement with Widder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296852,"accession_number":"0000950170-23-027241","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Personalis dismisses Deloitte as auditor, appoints BDO USA as new independent accounting firm","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Deloitte & Touche as independent auditor on June 6, 2023.","Deloitte's audit reports for FY2021 and FY2022 contained no adverse opinion or qualification.","No disagreements or reportable events between Company and Deloitte during the relevant periods.","BDO USA, LLP was appointed as new auditor for FY2023, formally engaged on June 9, 2023.","Deloitte provided a letter to SEC agreeing with the Company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296851,"accession_number":"0000950170-23-023232","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Personalis stockholders elect Bloom and Myers to board; ratify Deloitte; approve exec compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Olivia K. Bloom elected with 29.0M votes for, 0.2M withheld; Woodrow A. Myers Jr. elected with 25.4M for, 3.9M withheld.","Ratification of Deloitte & Touche as independent auditor for FY2023: 40.6M for, 0.04M against, 0.2M abstentions.","Non-binding advisory vote on executive compensation approved: 28.6M for, 0.5M against, 0.2M abstentions, 11.5M broker non-votes.","Over 87% of outstanding shares (40.8M of 46.8M) present, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296850,"accession_number":"0000950170-23-017142","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q1 revenue $18.9M (+24% YoY); net loss $28.7M; guides Q2 rev $16-17M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $18.9M in Q1 2023, up 24% from $15.2M in Q1 2022.","Net loss of $28.7M ($0.61 per share) vs $26.8M loss in Q1 2022.","Pharma/enterprise revenue $15.9M (+35% YoY); includes $9.5M from Natera.","Cash and investments $148.9M; full-year 2023 revenue guidance $68-72M, net loss ~$103M.","Appointed Chris Hall CEO; promoted Aaron Tachibana to COO and Richard Chen to EVP/CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":18860000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317217,"accession_number":"0001193125-23-064524","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Personalis appoints Christopher Hall as CEO, Aaron Tachibana as COO, Richard Chen as EVP R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Tachibana appointed COO (also CFO); $515k salary, 60% bonus, option for 450k shares vesting 36 months.","Christopher Hall appointed CEO (also President); $550k salary, 80% bonus, option for 400k shares vesting 36 months.","Richard Chen promoted to EVP R&D (also CMO); $500k salary, 60% bonus, option for 250k shares vesting 36 months.","Hall appointed Class II director, term until 2024 annual meeting.","Severance: Tachibana/Chen get 9/12 months base salary; Hall gets 12 months base on non-CIC/CIC termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317216,"accession_number":"0000950170-23-004085","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports Q4 2022 revenue $16.7M, net loss $31.1M; guides FY2023 revenue $68-72M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $16.7M, full year $65.0M; net loss Q4 $31.1M ($0.67/share), full year $113.3M ($2.48/share).","Cash and investments $167.7M at Dec 31, 2022; FY2023 cash usage guided to ~$75M, down from $119M in 2022.","Partnership with Moderna for genomic testing in personalized cancer vaccine trials; MRD validation study with Criterium and ABRCC.","Strategic review completed; new focus on MRD, personalized cancer vaccines, and pharma clinical trial support.","FY2023 net loss guided to ~$103M, improved from $113M in 2022 due to headcount reduction savings."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":65047000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317215,"accession_number":"0000950170-23-000863","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["2.05","7.01"],"status":"ready","headline":"Personalis to cut ~30% of workforce; $3M severance, $17M savings in 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction of up to ~30% of workforce, expected completion March 20, 2023.","Estimated ~$3M in severance and benefit costs, mainly Q1 2023, all cash expenditures.","Expects ~$17M net operating cost savings for remainder of 2023, ~$20M annualized.","Board approved reduction on January 16, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317214,"accession_number":"0000950170-23-000121","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis prelim Q4 revenue $16.7M; FY2022 $65M, above guidance of $63-64M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 revenue from biopharma and other customers grew 42% YoY to $56.6M.","VA MVP revenue fell 82% to $8.4M for FY2022; remaining unfulfilled orders ~$9.1M.","Preliminary cash and equivalents totaled $167M as of Dec 31, 2022.","Management plans to extend cash runway while focusing on key product opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":65047000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335500,"accession_number":"0001193125-22-304802","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Personalis CEO John West retires; CFO Aaron Tachibana named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO John West to retire as CEO and director effective Dec 31, 2022; will serve as advisor.","CFO Aaron Tachibana appointed interim CEO; Christopher Hall named President, effective Dec 31, 2022.","West receives 12 months base salary severance, COBRA subsidy, and 24-month equity acceleration.","West to provide consulting services from Jan 4 to Jun 30, 2023 at $5,000/month; option exercise extended to Dec 31, 2023.","Board initiates search for permanent CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335499,"accession_number":"0000950170-22-025225","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis resolves VA MVP contract protest; stop-work order lifted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["U.S. Department of Veterans Affairs MVP contract protest resolved in Personalis' favor.","Stop-work order lifted November 15, 2022; services can resume.","Initial task order valued up to $10 million for whole genome sequencing.","Contract award announced September 2022; now clear of protest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335498,"accession_number":"0000950170-22-021214","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q3 revenue $14.9M; core biopharma up 73% YoY; FY2022 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 revenue $14.9M vs $22.3M in Q3 2021; biopharma ex-VA revenue $14.9M (+73% YoY).","Net loss $26.5M ($0.58 EPS) vs net loss in prior year; cash $192.8M as of Sept 30, 2022.","FY2022 guidance: total revenue $63-64M, biopharma ex-VA $55.5-56.5M, net loss $111-114M.","Won exclusive 5-year VA MVP contract (subject to bidder protest); initial order received.","Appointed Christopher Hall as SVP, Diagnostic Business; launched NeXT Dx marketing and research collaborations with BC Cancer and Duke."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":48325000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-02T23:59:59+00:00|335498"}